



MARKET RELEASE

30 December 2016

Actinogen Medical Limited

TRADING HALT

The securities of Actinogen Medical Limited (the “Company”) will be placed in Trading Halt Session State at the request of the Company, pending the release of an announcement by the Company. Unless ASX decides otherwise, the securities will remain in Trading Halt Session State until the earlier of the commencement of normal trading on Wednesday, 4 January 2017, or when the announcement is released to the market.

Security Code: ACW

Sebastian Bednarczyk
SENIOR ADVISER, LISTINGS COMPLIANCE (PERTH)



Actinogen Medical

30 December 2016

Ms Anjuli Sinniah
ASX Operations
Level 40 Central Park
152-158 St George's Terrace
PERTH WA 6000

Via Email

Dear Anjuli

Trading Halt Request

In accordance with ASX Listing Rule 17.1, the Company hereby requests that its securities be placed into an immediate trading halt pending an announcement regarding Actinogen Medical's application to the FDA to initiate its XanADu Phase II clinical trial in the US of Xanamem in the treatment of Alzheimer's disease.

The Company requests that trading in its securities be halted until after the expected announcement is made or until the market opens on Wednesday, 4 January 2017, whichever is the earlier.

The Company is not aware of any reason why this trading halt request should not be granted.

Yours sincerely

Peter Webse
Company Secretary

About Actinogen Medical

Actinogen Medical (ASX: ACW) is an ASX-listed biotech company focused on innovative approaches to treating cognitive decline that occurs in chronic neurodegenerative and metabolic diseases. Xanamem™, Actinogen's lead candidate drug, blocks excess production of the stress hormone cortisol in the brain. There is growing evidence that chronic stress and excess cortisol leads to changes in the brain affecting memory, and to the development of amyloid plaques and neural death – all hallmarks of Alzheimer's disease. In 2016, the Company initiated XanADu, a Phase II efficacy and safety trial of Xanamem™ in mild Alzheimer's disease.

About Xanamem™

Xanamem™ is being developed as a promising new therapy for Alzheimer's disease, a condition with a multibillion dollar market potential. In the US alone, the cost of managing Alzheimer's disease in 2013 was estimated to be US\$250bn, and is set to increase to US\$1 trillion by 2050, outstripping the treatment costs of all other diseases. Alzheimer's disease is now the second leading cause of death in Australia, behind ischaemic heart disease. Xanamem™'s novel mechanism of action sets it apart from other Alzheimer's treatments. It works by blocking the excess production of cortisol - the stress hormone - in the hippocampus and frontal cortex, the areas of the brain most affected by Alzheimer's disease.